Stelara

TABLE OF CONTENTS

4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Stelara : Crohn’s disease
19 Stelara : Psoriatic arthritis (PsA)
33 Stelara : Ulcerative colitis
40 Stelara : Psoriasis

LIST OF FIGURES
11 Figure 5: Filgotinib for Crohn’s disease – SWOT analysis
12 Figure 4: Filgotinib for Crohn’s disease – SWOT analysis
13 Figure 21: Datamonitor Healthcare’s drug assessment summary of Stelara in Crohn’s disease
36 Figure 11: Datamonitor Healthcare’s drug assessment summary of Cimzia in Crohn’s disease
37 Figure 25: Datamonitor Healthcare’s drug assessment summary of Tysabri in Crohn’s disease
38 Figure 6: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
52 Figure 28: Datamonitor Healthcare’s drug assessment summary of ozanimod in Crohn’s disease
53 Figure 15: Upadacitinib for Crohn’s disease – SWOT analysis

LIST OF TABLES
5 Table 1: Stelara drug profile
17 Table 2: Stelara sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
20 Table 3: Stelara drug profile
22 Table 4: Stelara pivotal trial data in psoriatic arthritis
34 Table 5: Stelara drug profile
41 Table 6: Stelara drug profile
43 Table 7: Stelara pivotal trial data in adult psoriasis
46 Table 8: Stelara pivotal trial data in adolescent psoriasis
47 Table 9: Stelara late-phase trial data in psoriasis
49 Table 10: Cumulative rates of adjudicated major adverse cardiovascular events in five-year follow-up study on Stelara
patients
49 Table 11: Treatment-emergent infections in patients treated with Stelara through up to five-year follow-up